glp 1 and covid GLP-1 Agonists the Vagus Nerve: Are We Finally Approaching a Breakthrough in Long COVID? GLP-1 and COVID-19: Safety Timing

In a placebo-controlled trial, weekly subcutaneous semaglutide led to larger reductions in BMI (16.1% with semaglutide and +0.6% with placebo), body weight (15.3 kg with semaglutide and +2.4 kg with placebo), waist circumference, glycated hemoglobin levels, lipid parameters (excluding HDL), and alanine aminotransferase at 68 weeks versus placebo [14]

The startup is now looking ahead to an IPO, having filed its S-1 this summer, Business Insider first reported in October

doi: 10.1056/NEJM199309303291401 17 CorbinKDDriscollKAPratleyRESmithSRMaahsDMMayer-DavisEJet al

On the other hand, a BMI below 27 without additional health problems does not qualify them to receive a prescription

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines